Aspect Biosystems raises $20m for human bioprinting

Further boost for 3D bio-printing sector as Aspect Biosystems announces a multimillion funding round for advanced therapies.

Biotechnology company and pioneer in the 3D printing of human tissues, Aspect Biosystems has announced a $20 million funding [1] round to advance its search for advanced therapies. The announcement further fuels capital funding growth for bioprinting.

Longevity.Technology: 3D bioprinting is very much an emerging regenerative technology; we’re particularly interested in Aspect’s combined approach of platform and support services, where, we expect, commercial upside will come through licensing.  

The funding round was led by Radical Ventures, a VC that invests in ideas and entrepreneurs seeking to use deep tech to solve global problems. It also attracted participation from existing investors including Pallasite Ventures and Rhino Ventures.

Aspect is developing technology which, it believes, can “transform how we heal injury and disease”. Its technology platform creates living human tissue with “unprecedented levels” of control and precision, and the tech can be applied to:

  • Modelling muscle contraction;
  • Micro­patterning an immuno-oncology model;
  • Protecting the viability and integrity of stem cells;
  • Creating a perfusable blood-brain barrier model.

In order to translate the tech into commercial therapies, the Aspect team are developing global partnerships and creating a ‘pipeline’ of regenerative therapies that brings together emerging technologies in 3D printing, microfluids, cell biology and materials science.

Longevity Technology Aspect Biosystems 3d Bioprinting
Aspects’ combined hardware, software and services model (Source: Aspect Biosystems)

“This funding speaks to the power of our technology and strategy in addressing multiple applications in therapeutic discovery and regenerative medicine and will allow us to accelerate internal innovation and expand our global partnerships,” said Tamer Mohamed, CEO, Aspect Biosystems.

“With our technology platform, interdisciplinary team of scientists and engineers, and leading collaborators, we are developing a new wave of solutions that have the potential to transform how we heal injury and disease.”

Interest in 3D bioprinting is surging; Grand View Research projects a market growth of just under 20% year-on-year between now and 2026 spurred by improvements in technology and materials. New developments are crowding onto market; for example, last week we covered a study that has successfully grown ‘mini livers’ in a lab within 90 days.

Development is accelerating and capital is flowing into the 3D bio-printing sector. Companies such as Aspect, which are at the forefront of these developments, will feel very optimistic about the future indeed and we feel their optimism is well-founded.

[1] https://bwnews.pr/2v6QjJs

Main picture source: Aspect Biosystems

 

Carla Heyworth
Carla is sub editor at Longevity.Technology and she's the glue that keeps the team on track and the articles rolling-out. She has an extensive background in B2B communications, events and marketing. Carla's a visual person and can often be found behind a camera or editing photos

Latest articles

Building an artificial immune system

DoD-funded ThirdLaw Technologies to harness the power of ‘spiroligomers’ to rapidly build new small molecules for Longevity therapies. Far from the world of stock market...

Neurotech is the new blue ocean

Alon Braun, Co-Founder, Neurotech Analytics.

Amazon and K4Connect demonstrate scalability for agetech

Covid-19 has been difficult for everyone, but particularly for people over the age of 65 who may spend months shut away from loved ones...

“Avoid the use of DQ as a senolytic therapy”

Forever Healthy Foundation issues risk-benefit analysis on dasatinib + quercetin as a senolytic. The Forever Healthy Foundation today published its latest risk-benefit analysis, which explores...